Business News • PR NewsWire • Amgen Announces Results From Phase 3 PAVES Study Evaluating Neulasta® (pegfilgrastim) In Patients With Colorectal Cancer

Amgen Announces Results From Phase 3 PAVES Study Evaluating Neulasta® (pegfilgrastim) In Patients With Colorectal Cancer

Amgen Announces Results From Phase 3 PAVES Study Evaluating Neulasta® (pegfilgrastim) In Patients With Colorectal Cancer

THOUSAND OAKS, Calif., Jan. 26, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta® (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the...

View More : http://www.prnewswire.com/news-releases/amgen-announces-results-from-phase-3-paves-study-evaluating-neulasta-pegfilgrast...

Releted News by prnewswire

Answer Financial® Inc. has broken ground on new Knoxville, Tennessee Sales Center